DND Pharmatech to Present Preclinical Results of New Obesity Drug 'DD18' at International Conference in November

Preclinical Results of CRFR2-Selective UCN2 Analog 'DD18'
To Be Unveiled for the First Time in a Poster Presentation at ObesityWeek 2026

DND Pharmatech announced on August 25 that it will present the preclinical research results of its new obesity treatment candidate, 'DD18', at 'ObesityWeek 2026', the world's largest obesity-focused conference, to be held in Washington, D.C., USA in November.

DND Pharmatech company logo image. DND Pharmatech

At the conference, DND Pharmatech will unveil the preclinical results of DD18, a selective urocortin-2 (UCN2) analog targeting the corticotropin-releasing factor receptor 2 (CRFR2), for the first time in a poster presentation.

UCN2 is an endogenous peptide that acts selectively on CRFR2 and is known to influence lipid and skeletal muscle metabolism through a mechanism different from that of incretin-based treatments. DND Pharmatech is developing the UCN2 analog DD18, which has been engineered for high selectivity and long-lasting effects on CRFR2.

Seulgi Lee, CEO of DND Pharmatech, stated, "UCN2 is emerging as a promising next-generation target in obesity therapeutics, as demonstrated by the recent conclusion of large-scale global technology transfer agreements. We proactively began new drug development based on UCN2 about two years ago and have since developed DD18 in-house."

She added, "At ObesityWeek 2026, we will present the preclinical results of DD18 on a global stage, which will enhance the technological value of our pipeline and actively seek commercialization opportunities with potential global partners."

Based on the results of this preclinical study, DND Pharmatech plans to accelerate further development, aiming to begin clinical trials of DD18 in 2027 while simultaneously pursuing worldwide business development discussions.

This content was produced with the assistance of AI translation services.